In drug development, solid performance in large-scale clinical trials is crucial.There was some good news in the clinical sphere for Gilead Sciences (GILD 2.74%) on Thursday, and this drove its stock price up by almost 3% that trading session. A late-stage clinical trial of an investigational drug yielded encouraging initial results, hence the rise. In comparison, the S&P 500 index inched up by 0.8% on the day.HIV drug does well in the labGilead's news was that its second phase 3 trial of HIV drug lenacapav ...

Gilead's twice-yearly shot reduced HIV infections by 96% in a second large study, the company said Thursday.The positive phase three trial data on Lenacapavir sets the stage for likely approval by the U.S. Food and Drug Administration for HIV prevention."Now that we have a comprehensive dataset across multiple study populations, Gilead will work urgently with regulatory, government, public health and community partners to ensure that, if approved, we can deliver twice-yearly lenacapavir for PrEP worldwide, ...

Gilead Sciences, Inc. (NASDAQ:GILD) Baird Global Healthcare Conference September 10, 2024 10:50 PM ET Company Participants Johanna Mercier - Chief Commercial Officer Conference Call Participants Brian Skorney - Baird Brian Skorney [Starts abruptly] biotech analysts here. [Technical Difficulty] to have presenting with us next, Gilead Sciences. Thanks for coming today. We really appreciate it. Maybe just to kick things off, I'll kind of ask the general question to give a broad overview of what Gilead does and ...

Gilead Sciences, Inc. (NASDAQ:GILD) Baird Global Healthcare Conference September 10, 2024 10:50 PM ET Company Participants Johanna Mercier - Chief Commercial Officer Conference Call Participants Brian Skorney - Baird Brian Skorney [Starts abruptly] biotech analysts here. [Technical Difficulty] to have presenting with us next, Gilead Sciences. Thanks for coming today. We really appreciate it. Maybe just to kick things off, I'll kind of ask the general question to give a broad overview of what Gilead does and ...

Gilead Sciences, Inc. (NASDAQ:GILD) Wells Fargo 2024 Healthcare Conference September 4, 2024 11:00 AM ET Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Participants Mohit Bansal - Wells Fargo Mohit Bansal Good morning, my name is Mohit Bansal. I'm one of the biopharma analyst here at Wells Fargo. And this is my third year hosting it. And I think... Andrew Dickinson Third year's [indiscernible]. Mohit Bansal So thank you, Andy, for joining us today. Andrew Dickinson Thank you ...

Gilead Sciences, Inc. (NASDAQ:GILD) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 12:20 PM ET Company Participants Daniel O'Day - Charman & CEO Andrew Dickinson - Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Thanks for joining us, everybody. I'm Terence Flynn, the U.S. biopharma analyst here at Morgan Stanley. Before we get started, for important disclosures, please see the Morgan Stanley research disclosure website at www.morg ...

Gilead Sciences, Inc. (NASDAQ:GILD) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 12:20 PM ET Company Participants Daniel O'Day - Charman & CEO Andrew Dickinson - Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Thanks for joining us, everybody. I'm Terence Flynn, the U.S. biopharma analyst here at Morgan Stanley. Before we get started, for important disclosures, please see the Morgan Stanley research disclosure website at www.morg ...

Merck & Co. MRK and Gilead Sciences Inc. GILD are two pharmaceutical heavyweights whose stocks tell very different stories.Rahway, New Jersey-based Merck just flashed a Death Cross, signaling potential trouble ahead. Foster City, California-based Gilead is basking in a Golden Cross, a sign of bullish momentum.Merck: Treading On Thin IceMerck, known for its diverse lineup of drugs and vaccines, is seeing its stock wobble. Despite a decent climb of 8.72% over the past year, recent technical signals are turnin ...

Sundry Photography When looking at the last few weeks, we can make statements about Gilead Sciences Inc. (NASDAQ:GILD), which we could seldom make in the last few years. Gilead Sciences not only outperformed the market, but we also had a streak of nine up days in a row. Looking at the last three months, Gilead Sciences performed great and especially since the beginning of July 2024, Gilead Sciences started to outperform the S&P 500 (SPY). Data by YCharts My last article about Gilead Sciences was publish ...

Ridofranz/iStock via Getty Images My previous article, “Gilead Sciences: Seriously Undervalued At Peak Pessimism,” caused quite a stir in the comments, particularly from those Seeking Alpha readers who remain pessimistic about Gilead Sciences, Inc.'s (NASDAQ:GILD) business prospects. However, that hasn't stopped the company's stock price from rising more than 23% in less than three months. In this article, I'll present an analysis of the sales of its HIV and oncology franchises, the successes and failur ...